Pro Medicus: Broker Eyes Share Surge

Shares in Pro Medicus Ltd (ASX: PME) have experienced a significant downturn over the past year, more than halving in value. This decline has occurred against the backdrop of a broader technology sector sell-off, rather than being driven by company-specific negative news. The last notable announcement from Pro Medicus was on December 1st, detailing a substantial $25 million, seven-year contract secured in the United States.

Navigating the Tech Sell-Off: A Closer Look at Pro Medicus

Analysts at Morgans have recently provided their perspective on Pro Medicus, suggesting that the steep decline in its share price may stem from investor concerns about the potential impact of artificial intelligence (AI) on the economics of premium Software as a Service (SaaS) platforms in the imaging sector. However, Morgans posits that this concern might be a misinterpretation of Pro Medicus’s role and value proposition.

While acknowledging the growing influence of AI in the radiology field, where Pro Medicus operates, Morgans highlights that AI’s primary contribution lies in enhancing efficiency and streamlining workflows.

• AI’s Role in Radiology:
  • Global demand for medical imaging, particularly CT and MRI scans, has consistently outpaced the availability of radiologists for over a decade.
  • The inherent complexity of these imaging modalities often leads to workflow bottlenecks, extended reporting times, radiologist fatigue, and increased pressure for cost-effective solutions.
  • AI’s core value proposition in healthcare is efficiency, achieved through automation, improved consistency, and smarter prioritisation of tasks.
  • Current AI applications in radiology include image quality checks, automated labelling, and the identification of clear negative scans or straightforward cases.
  • Crucially, these AI functions support, rather than replace, the fundamental need for radiological expertise, enterprise workflow management, data routing, and high-performance visualisation.

Pro Medicus: The Essential Infrastructure Provider

Morgans argues that while AI tools are becoming increasingly powerful, they require robust underlying infrastructure to function effectively. This is precisely where Pro Medicus excels. The company’s proprietary product suite is designed to manage the compression and decompression of large radiology files, a critical component of the modern imaging ecosystem.

As the Morgans team explained, Pro Medicus provides this essential infrastructure. Therefore, the accelerating adoption of AI could, in fact, strengthen Pro Medicus’s business case, positioning its product as a more compelling solution compared to its peers, at least in the medium term.

A Strong Competitive Moat

Morgans also addresses concerns about potential competition, noting that while some start-ups are emerging with end-to-end imaging solutions, these are currently small, unproven, and not yet enterprise-ready. Furthermore, the healthcare sector, particularly in procurement, tends to be risk-averse, with lengthy testing and evaluation cycles.

The analysts acknowledge that risks are inherent in any investment, as they always have been. However, they do not perceive these risks as existential threats to Pro Medicus in the next five to ten years. They believe that Pro Medicus is well-positioned to secure additional large contracts, thereby locking in guaranteed minimum revenues for the next seven to ten years, indicating that growth is far from plateauing.

Morgans has set a 12-month price target of $290 for Pro Medicus shares. This represents a significant potential upside of 79.9% from the current trading price of $161.17.

Pro Medicus is scheduled to release its first-half financial results on Thursday, February 12th.